作为课题负责人主持基金：

1.     国家自然科学基金。MmpS5-MmpL5外排系统在结核分枝杆菌对贝达喹啉耐药中的作用及机制研究。

2.     北京市自然科学基金。靶向氧化磷酸化途径的新型药物方案的协同作用机制及其抗结核作用研究。

3.      北京市卫生健康委员会。高层次公共卫生技术人才建设项目。

4.     青海省科学技术厅应对新型冠状病毒感染肺炎防控重点专项。新型冠状病毒感染者的快速诊断与传播力研究。

5.     北京市自然科学基金。维拉帕米对增强氯苯吩嗪抗结核活性和减少耐药性发生的影响。

6.     北京市优秀人才青年骨干项目。抗耐药结核化合物4ph5-2作用机制和联合化疗方案研究。

7.   北京市医管局“青苗”计划。mmpS5-mmpL5系统在结核分枝杆菌对氯苯吩嗪耐药中的作用。

代表性论著：

1.    Xu J*, Li DS, Shi JH, Wang B, Ge F, Guo ZY, Mu XP, NuermbergerEL, Lu Y*.Bedquiline ResistanceMutations: Correlations with Drug Exposures and Impact on the Proteome in M.tuberculosis. Antimicrob Agents Chemother. 2023.67(7)。

2.  XuJ, Converse PJ, Upton AM, Mdluli K, Fotouhi N, NuermbergerEL. Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquilineagainst a resistant Rv0678 mutant in a mouse model of tuberculosis. AntimicrobAgents Chemother. 2021. 65(4):e02418-20. doi: 10.1128/AAC.02418-20.

3.    Xi AQ, Zhuo M, Dai JT, Ding YH, Ma XZ, Ma XL, WangXY, Shi LM, Bai HY, Zheng HY, Nuermberger E, Xu J*(通讯作者). Epidemiologicaland Clinical Characteristics of Discharged Patients Infected With SARS-CoV-2 onthe Qinghai Plateau. J Med Virol, 2020; 92(11):2528-2535. doi: 10.1002/jmv.26032.

4.    Xu J, Li SY, Almeida DV, Tasneen R,Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Contributionof pretomanid to novel regimens containing bedaquiline with either linezolid ormoxifloxacin and pyrazinamide in murine models of tuberculosis. AntimicrobAgents Chemother. 2019;63(5):e00021-19. doi: 10.1128/AAC.00021-19.

5.    Xu J#, Wang B#, Fu L, Zhu H, Guo S, HuangH, Zhang Y, Lu Y. In vitro and in vivo activities of theriminophenazine TBI-166 against Mycobacterium tuberculosis. Antimicrob AgentsChemother. 2019;63(5).:e02155-18

6.    RenJ#, Xu J#(co-first author), Zhang G, Xu C, Zhao L,You X, Wang Y, Lu Y, Yu L. Design, synthesis, and bioevaluation of a novelclass of (E)-4-oxo-crotonamide derivatives as potent antituberculosis agents.Bioorganic & Medicinal Chemistry Letters. 2019. 29(4):539-543.

7.    Xu J, Tasneen R, Peloquin CA, Almeida DV, LiSY, Barnes-Boyle K, Lu Y, Nuermberger E.Verapamil Increases the Bioavailabilityand Efficacy of Bedaquiline but Not Clofazimine in a Murine Model ofTuberculosis. Antimicrob Agents Chemother. 2018; 62(1).

8.    Xu J, Wang B, Hu M, Huo F, Guo S, JingW, Nuermberger E, Lu Y. Primary Clofazimine and Bedaquiline Resistance amongIsolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrob AgentsChemother.2017;61(6). pii: e00239-17.

9.    Xu J, Wang JX, Zhou JM, Xu CL, Huang B, Xing Y, WangB, Luo R, Wang YC, You XF, Lu Y, Yu LY. A novel protein kinase inhibitor IMB-YH-8withanti-tuberculosis activity. Sci Rep.2017;7(1):5093

10.    Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K,Upton AM, Jin H, Zheng M, Zhao W, Li P. In vitro and in vivo activity ofclofazimine against Mycobacterium tuberculosis persisters. Int J Tuberc LungDis. 2012;16(8):1119-25.

11.  Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C,Chen M, Zhou L, Zhao W, Fu L, Lu Y. Oral bioavailability ofrifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dosecombination compared with the separate formulations in healthy Chinese malevolunteers. Clin Ther. 2013;35(2):161-8.

12.     史静华，李东硕，岑山，陆宇，徐建。结核分枝杆菌MmpL5蛋白与贝达喹啉及氯法齐明相互作用的关键结合区域研究。中国抗生素杂志。2024,49（8）:890-897.

13.      葛菲，朱慧，程凯，陆宇，徐建。高效液相色谱-质谱联用法测定血浆中异烟肼及其代谢物浓度的研究。中国防痨杂志. 2024,46(05)：549-556.

14.     李东硕，王彬，陆宇*，徐建*(通讯作者)。结核分枝杆菌膜蛋白MmpS5-MmpL5的表达及功能研究。中国防痨杂志. 2022,44(03)：227-233.